FDA Determines Regulatory Review Period for WELIREG Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for WELIREG, a human drug product, following submissions to the U.S. Patent and Trademark Office (USPTO) for patent extension.